| Presentation preference | Oral presentation |
| Title | Real-World Treatment Patterns and Ocular Morbidity in Patients with Uveitic Macular Edema (UME) Secondary to Non-Infectious Uveitis (NIU) in the United States (US) |
| Accept poster if oral is not possible ? | Yes |
| Purpose | To evaluate treatment patterns in NIU patients and characterize the unmet need for new UME therapies. |
| Methods | Electronic records of patients treated by US retina specialists from the Vestrum Health® database were analyzed. NIU patients ≥18 years old with ≥2 separate NIU diagnoses within 120 days of each other and ≥1 follow-up visit between 2017–2024 were included. UME was identified by International Classification of Diseases code and electronic health record documentation. |
| Results | Among 35,874 NIU eyes, 46% had a UME diagnosis. In year 1, NIU and UME eyes had about 1 visit every 2 months per eye (median 17–19 months of follow-up). Topical steroids, intravitreal (IVT) Ozurdex, and subtenon triamcinolone were the most common treatments in both cohorts. Combined treatments were used as first-line therapy in 21% of NIU and 24% of UME eyes. At baseline (BL), 63% of UME eyes were pseudophakic, yet 13% of phakic eyes underwent cataract surgery within 1 year. Glaucoma was prevalent at BL in both NIU (21%) and UME eyes (28%), with 13% of UME eyes developing glaucoma by year 1. Visual acuity losses were observed: 20% and 21% of NIU and UME eyes, respectively, lost ≥5 letters; 9% and 10% lost ≥15 letters. |
| Conclusion | In the US, locally administered corticosteroids (CS) remain the standard of care for NIU-UME, but associated side effects limit long-term use and increase morbidity. The absence of non-CS local IVT therapies highlights an unmet need for effective, safer alternatives. Two global, randomized, controlled, identical, phase 3 trials are investigating vamikibart, an IVT anti-interleukin-6 monoclonal antibody, in UME (NCT05642312, NCT05642325). |
| Conflict of interest | Yes |
| Details of conflicting interests | Quan Dong Nguyen. Consultant: Alumis, Genentech, Inc., Kriya, Regeneron, Rezolute; Research: Acelyrin, Alumis, Priovant, Regeneron
Lu Chen: Employee: Genentech, Inc.; Stocks/Stock Options: Roche
Parul Dayal: Employee: Genentech, Inc.; Stocks/Stock Options: Roche
Navdeep Pal: Employee: Genentech
Ivo Stoilov: Employee: Genentech, Inc.; Stocks/Stock Options: Roche
Marina Mesquida: Employee: F. Hoffmann-La Roche Ltd.; Stock/Stock Options: Roche
Zdenka Haskova: Employee: Genentech, Inc.; Stocks/Stock Options: Roche
Laura Steeples: Employee: Roche Products Ltd.; Stock/Stock Options: Roche |
1
| Last name | NGUYEN |
| Initials of first name(s) | QD |
| Department | Byers Eye Institute, Stanford University |
| City | Palo Alto, CA |
| Country | United States |
2
| Last name | CHEN |
| Initials of first name(s) | L |
| Department | Genentech, Inc. |
| City | South San Francisco |
| Country | United States |
3
| Last name | DAYAL |
| Initials of first name(s) | P |
| Department | Genentech, Inc. |
| City | South San Francisco |
| Country | United States |
4
| Last name | PAL |
| Initials of first name(s) | N |
| Department | Genentech, Inc. |
| City | South San Francisco |
| Country | United States |
5
| Last name | STOILOV |
| Initials of first name(s) | I |
| Department | Genentech, Inc. |
| City | South San Francisco |
| Country | United States |
6
| Last name | MESQUIDA |
| Initials of first name(s) | M |
| Department | F. Hoffmann-La Roche AG |
| City | Basel-Stadt |
| Country | Switzerland |
7
| Last name | HASKOVA |
| Initials of first name(s) | Z |
| Department | Genentech, Inc. |
| City | South San Francisco |
| Country | United States |
8
| Last name | STEEPLES |
| Initials of first name(s) | L |
| Department | Roche Products Ltd. |
| City | Welwyn |
| Country | United Kingdom |
